Regulatory context: no codified refusal right, but clear adjacent obligations
No current U.S. federal rule or accreditation standard names a patient right to refuse AI-assisted care as a distinct category. Instead, healthcare organizations must build clinical AI opt-out procedures from adjacent obligations. ONC’s HTI-1 Final Rule requires certified health IT to disclose source attributes for predictive decision support interventions, giving clinicians the information needed to evaluate and, where appropriate, decline an AI output. FDA’s AI/ML SaMD Action Plan expects manufacturers to support ongoing human oversight across the device lifecycle. HHS OCR’s 2024 Section 1557 rule goes further, placing nondiscrimination compliance responsibility for AI-based decision support tools directly on the covered entity, not the vendor. AMA policy reinforces that physicians retain ultimate responsibility for care decisions when AI is used. Together, these sources support a healthcare AI consent policy grounded in transparency, human oversight, and organizational accountability, even without a single governing statute on refusal itself.
Build refusal procedures from existing transparency, oversight, and nondiscrimination duties. Do not wait for a standalone federal “AI refusal right” before defining runtime and governance controls.
Governance ownership, overrides, and accountability
Because Section 1557 places compliance responsibility on the covered entity rather than the AI vendor, ownership of the refusal policy should sit with compliance and clinical governance functions, not IT alone. IT and engineering teams implement the technical controls, but governance defines who can authorize an override of the refusal-enforced state and requires that every override be logged for audit purposes. This separation matters for accountability: a technical control without governance ownership can be reconfigured without oversight, and a governance policy without technical enforcement is only a document. Organizations should also treat the policy as a living artifact. ONC, FDA, and HHS OCR guidance on AI in clinical settings has continued to evolve over the past year, and a refusal policy written against current rules should include a scheduled review tied to regulatory monitoring rather than a one-time publication.